Dr. Hashim Mann, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 235
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
VA license 0101274148 · MA license 278953
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medical College of Virginia Hospitals Richmond, VA
- Vcu Health Tappahannock Hospital Tappahannock, VA
Medical groups
- Mcv Associated Physicians (1,807 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 235
- Services billed
- 754
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 199 | 91 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 119 | 25 |
| Established patient office or other outpatient visit, 20-29 minutes | 98 | 69 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 62 | 28 |
| Established patient office or other outpatient visit, 10-19 minutes | 37 | 33 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 27 | 26 |
| New patient office or other outpatient visit, 30-44 minutes | 20 | 20 |
| Hospital discharge day management, 30 minutes or less | 16 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Richmond, VA | 250 |
| Dexamethasone Other prescribers in Richmond, VA | 203 |
| Lenalidomide | 95 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Richmond, VA | 75 |
| Pomalyst (pomalidomide) | 69 |
| Revlimid (lenalidomide) | 46 |
| Gabapentin Other prescribers in Richmond, VA | 33 |
| Oxycodone Hcl Other prescribers in Richmond, VA | 30 |
| Ondansetron Hcl Other prescribers in Richmond, VA | 21 |
| Ondansetron Odt (ondansetron) Other prescribers in Richmond, VA | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $2,928 in total to this clinician.
| Janssen Scientific Affairs, LLC | $1,388 |
|---|---|
| Janssen Biotech, Inc. | $1,360 |
| Genzyme Corporation | $112 |
| Pfizer Inc. | $69.79 |
| Consulting Fee | $2,648 |
|---|---|
| Food and Beverage | $281 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC Mar 11, 2025 | Consulting Fee TECVAYLI · Oncology | $1,388 |
| Janssen Biotech, Inc. Jan 3, 2025 | Consulting Fee TECVAYLI · Oncology | $1,260 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $262,997 in research payments for these studies, mostly to the institutions running them.
- A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexam…
Janssen Research & Development, LLC - M22-574 - Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. - Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. · Active, not recruiting · NCT06158841 - A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexam…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.